Navigation Links
New 'knock-out' gene model provides molecular clues to breast cancer
Date:9/5/2007

New insights into the role of estrogen receptor in mammary gland development may help scientists better understand the molecular origin of breast cancer, according to new research from the University of Cincinnati (UC).

About a decade ago, U.S. scientists at the National Institutes of Health (NIH) developed a standard estrogen receptor (ER) gene knock-out mouse model to study the estrogen receptors role in human diseases.

Unfortunately, because these mice lacked mammary glands as a consequence of genetic manipulation, using this model to study the relationship between the estrogen receptor and breast cancer proved ineffective, explains Sohaib Khan, PhD, professor of cell and cancer biology at UC.

Knocking out the estrogen receptor gene for the entire genome, as the NIH scientists did, doesnt just affect the function of the receptor in all estrogen-responsive organs. It also creates an imbalance in the bodys circulating sex hormone levels, which could affect other physiological functions, Khan adds. An alternative model was clearly needed to study the intricacies of estrogen receptors involvement in this disease.

Estrogen receptor is a cellular protein that binds with the hormone estrogen and facilitates action in different parts of the body, including the mammary gland. Research has shown that about 70 percent of breast cancer patients have estrogen receptor-positive breast cancer, meaning their tumors will have some beneficial response to anti-estrogen drugs like tamoxifen (ta-MOX-ee-fen, marketed as Nolvodex).

After two years of work, Khan says his team has developed a knock-out mouse model that will allow scientists to study the role of estrogen receptor in specific organs (for example, mammary glands) without affecting estrogen-signaling throughout the rest of its body.

Khan used what is called a conditional knock-out technique to develop a new mouse model that retains estrogen receptor in all tissues except mammary tissue, allowing scientists to study the receptors role in breast development and breast cancer.

Using this model, Khans team found that knocking out the gene only in mammary tissue resulted in abnormalities that compromised milk production in the nursing female. This suggests that estrogen expression is essential for normal duct development during puberty, pregnancy and lactation.

Khan and his coworkers report the creation of this model and its potential implications in an early online edition of the Proceedings of the National Academy of Sciences on Sept. 4, 2007, followed by the print issue Sept. 11, 2007. The study directly refutes previous research, which suggests that estrogen receptor in epithelial cells was not essential to normal mammary gland development.

Mammary tissue is made up of two cell typesstromal cells, which give the tissue structure, and epithelial cells, which make up the lining of the mammary gland and become cancerous in the majority of breast cancers.

Unlike other organs in the body, the mammary glands develop after birth in response to increases in circulating hormones. This triggers growth of a network of branched ducts throughout the breast tissue that do not change again until a woman becomes pregnant.

Even though the relationship between the estrogen receptor and breast cancer is well established, we still know very little about the receptors mechanism of action, explains Khan, corresponding author of the study. Unless we study those mechanisms more closely, improved strategies for breast cancer treatments will not be possible.

Premenopausal women with breast cancer are currently given five years of tamoxifen, a drug that blocks the estrogen receptor action in cancer cells, to prevent recurrence. Studies have shown that the drug reduces recurrence in 40 percent of the women who take it, but Khan says many women eventually develop resistance to the drug.

Using this unique mouse model, UC researchers are currently collaborating with scientists at Dana Farber Cancer Institute/Harvard Medical School to understand the relationship between estrogen-signaling and oncogene-mediated breast cancer development. Future findings from these studies could help scientists better understand the molecular origin of breast cancer and develop new drugs to more effectively treat it.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati
Source:Eurekalert

Related medicine news :

1. Down syndrome simulated in animal model after successful chromosome transplantation
2. Novel computer model for breast cancer
3. MRI, To Detect Remodeling Of Heart and Help Preserve Function
4. Synthetic protein found to relieve arthritis symptoms in animal model
5. Researchers Develop Mouse Model Of Brain Tumor
6. New Model for understanding Tumor Metastasis
7. Mathematical Model Can Now Help Predict Asthma Risk
8. Model Kate Moss - Re-Birth After Humiliation
9. Heart transplanted infants better model for developing AIDS treatment
10. Mice model to study bacterial therapeutic pathway
11. Womens Self-Esteem Not Lowered By Seeing Ultra Thin Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will ... of Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention ... long been the gold standard for high-definition, in-ear earphones. This classic earphone has ...
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons ... to primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis ... Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive ...
(Date:1/17/2017)... ... 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey ... region, is launching a charity drive to raise awareness of heart disease and promote ... in America, and is responsible for 1 in every 4 deaths at the national ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Research Future published a Half Cooked Research Report on Endoscopy Devices ... 33.6 million during the period 2016 to 2022 from USD 28.7 ... ... examined as a swiftly growing market and expected to grow at ... in various regions.  The increasing growth in endoscopy procedures is influencing ...
(Date:1/17/2017)... KANSAS CITY, Mo. , Jan. ... (CHNC) has selected Velos and its flagship technology ... and multicenter initiatives. CHNC is a ... Neonatal Intensive Care Units at leading children,s hospitals ... consortium provides a benchmark of care and short-term ...
(Date:1/17/2017)...  Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is ... Inc. ("Anthera" or the "Company") (NASDAQ: ANTH ). ... the investigation by visiting the firm,s site: www.bgandg.com/anth .   ... its officers and/or directors have violated Sections 10(b) and 20(a) ... ...
Breaking Medicine Technology: